PLS-Design is developing several technologies to support the modulation of the immune system. Recent scientific findings provided more facts that a “simple” model of the immune system does not exist. The unfolding story of the interacting parts of the immune system seems much more complex than ever believed…but it also reflects the beautiness of nature’s strategies for survival.
It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change. – Charles Darwin
PLS-Design is considering this complexity in immune response and aims to modulate immune cells in the most fitting way:
- Local Modulation
By restricting the immune modulation to a localized format, systemic side reactions are essentially avoided. The modulation is induced locally, but the resulting changes in immune reaction will occur in the whole body. By focusing on local modulation and the use of thermosensitive hydrogels, higher concentrations and constant release rates of active substances can be safely reached.
Read more in “Local Modulation”.
- Tolerance Induction
The induction of immune tolerance is aimed at with a multi-level approach, to avoid therapy failure by e.g. secondary pathways signalling. PLS-Design is simultaniously targeting gene transcription, receptor signalling and inhibition of peripheral “danger” signals.
Read more in “Tolerance Induction”.
- Novel Adjuvants
In recent scientific findings the significant influence of the complement system on tolerance induction and vaccination has been highlighted. Complement system component 3 (C3) is the key player of the complement system. PLS-Design has developed technologies to inactivate C3 for tolerance induction or activate it for use as endogenous potent adjuvants in vaccinations.
Read more in “Novel Adjuvants”.
- Companion Diagnostics
PLS-Design has cloned and expressed a large array of recombinant allergens, especially insect venom allergens, for use in companion diagnostics (CDx) of immunotherapy. The success of immunotherapy depends on the correlation of the sensitization pattern of the patient and the available amount of corresponding allergens in the therapeutics. PLS-Design is using CDx to improve therapeutics for patients, especially for patients at risk to suffer from potentially life-threatining anaphylactic shock after insect stings.
Read more in “Companion Diagnostics”.
PLS-Design is using the full depth of available scientific knowledge from publications and patents, propriatory research data, as well as an extensive network to academic and clinical groups to provide the industry with the most fitting approach to modulate the immune system.
Recent reviews on immune system complexity and complement interactions:
Walker et al. 2013, Innate lymphoid cells – how did we miss them? Nature Reviews 13:75-100.
Ricklin 2012, Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 217:1057-66.